AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05579106 — intervention group
Intervention type: DEVICE
Intervention: Nociception Level Monitor (NOL) by Medasense Biometrics Ltd., Israel
Description: The NOL monitor measures various parameters via a sensor in a finger probe that is attached to the patient.~These parameters are:~* Temperature~* Galvanic skin response~* Accelerometer~* Photoplethysmograph (pulse rate, pulse rate variability, photoplethysmograph amplitude)~All this data is combined in an algorithm which produces a number between 0-100. Between 10-25 indicates adequate analgesia, below 10 too much analgesia, above 25 too little analgesia. No actions are taken based on this measurement.
Study NCT05579106 — intervention group
Intervention type: DEVICE
Intervention: Bispectral index (BIS)
Description: The BIS processes EEG information to provide a direct measurement of the patient's level of consciousness and insight into the effects of anesthesia on the brain.
Study NCT05579106 — intervention group
Intervention type: OTHER
Intervention: Questionnaire perception of the nurse on pain patient
Description: The investigators developed a questionnaire with 7-questions regarding the perception of the responsible nurse on the pain of the patient. When the investigators measured for 8 hours with the BIS and the NOL they will ask the nurse what his or her perception was of the pain of the patient. Eventually the investigators will compare the answers of this questionnaire with the NOL and BIS values that they observed, whether the information corresponds or not.
Study NCT05221736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-Guided Ethanol Sclerotherapy (UGES)
Description: Comparison between Ultrasound-Guided Ethanol Sclerotherapy (UGES) \& surgical excision in management of warthin tumor of parotid gland.
Study NCT05332366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Description: Cream for topical application
Study NCT05332366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Delgocitinib cream
Description: Cream for topical application
Study NCT05332366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Delgocitinib cream vehicle
Description: The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
Study NCT04003805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standardized Research E-cigarette (SREC)
Description: The device operates at a single output voltage (3.30 ± 0.05 V) and uses sealed disposable 3-mL cartridges with tobacco-flavored e-liquid (\~350 puffs/cartridge). The concentration of nicotine in e-liquid is 15 mg/mL, and the vehicle composition is 50:50 propylene glycol and glycerin. The device uses a battery that can be recharged via a micro USB port. A single charge is designed to sustain more than 400 puffs, which is more than the capacity of an e-liquid cartridge. The e-liquid and the aerosol are well-characterized in terms of chemical impurities and by-products (such as aldehydes), which are minimal. Additional information, including the results of pharmacokinetics study is available via NIDA website: https://www.drugabuse.gov/funding/supplemental-information-nida-e-cig
Study NCT04003805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Mini-Lozenge
Description: We will use commercially available nicotine mini-lozenges containing 2 or 4 mg nicotine/lozenge (Nicorette, manufactured by GlaxoSmithKline). Dose will be determined per instructions on the package (e.g, if smoking within 30 minutes upon awakening, then 4 mg dose will be prescribed).
Study NCT05290168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: abdominal Doppler
Description: 1. Inferior vena cava diameter and distensibility~2. Hepatic vein Doppler~3. Portal vein Doppler~4. Splenic artery and vein Doppler~5. Renal artery and vein Doppler
Study NCT02154217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Study NCT02154217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost/Timolol
Study NCT04782635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile based application
Description: Application basic function would be support and improve nutrition status of children. Personalization of goals and challenges, daily intake of calories, carbohydrates, proteins, fats, minerals and vitamins will be tracked, food logging, food tracking, meal and supplement reminders, recipes, visual cues (remaining calories) will be notified, episodes of vomiting, meals missed, diarrhea, nausea will be recorded , meal planned according to the food preferences of child, food composition table, nutrition blogs and articles
Study NCT04782635 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pamphlet
Description: A pamphlet which will be provide knowledge to the patients
Study NCT04577573 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensory brace
Description: A a size- and position-adjustable arm brace with weight-support capability and housing for vibration motors and EMG sensors. Position adjustment allows for physical therapists to find and recommend arm postures that are clinically relevant to~each person. The participant can then isometrically push/resist against the brace to strengthen target muscles while performing VR reach-to-touch. The person will receive visual feedback from the virtual environment to train movement performance and vibrotactile feedback at tendons to subconsciously adjust their muscle activation patterns
Study NCT06405880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist-led care pathway
Description: Participants in the intervention arm will receive the care using a shared decision-making pharmacist-led care pathway designed to guide the cardiovascular (CV) risk reduction process. The pharmacist-led care pathway is modelled after the largest CV risk reduction randomized controlled trial in a community pharmacy setting (RxEACH Study), and based upon the latest CV risk reduction guidelines, such as C-CHANGE. This pathway will be built into a computer web-based program and include step-by-step, algorithm-guided patient assessment to calculate the participant's estimated CV risk. The participant and pharmacist will be guided by the care pathway to review the participant's estimated CV risk and contributing CV risk factors and engage in shared decision-making to manage the participant's CV risk factors using lifestyle changes and/or pharmacological treatment as clinically appropriate.
Study NCT05787964 — intervention group
Intervention type: PROCEDURE
Intervention: Biological sample collection
Description: Whole blood (blood draw/phlebotomy) will be obtained to proceed with immunologic analysis of samples. Collection of biologic samples will occur up to 12 months.
Study NCT05261815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound Therapy
Description: Ultrasound Therapy improves the pain management in patients with herniation. It eases down the severity of symptoms as well.
Study NCT05261815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Laser Therapy
Description: Treatment of low disc herniation should be non-surgical, pharmacological and by physical therapy modalities. Laser radiation with high intensity used as a modality called high intensity laser therapy. It is used to relieve the pain by three process; Photo-chemical, Photo-thermal, Photo-mechanical. High Intensity Laser Therapy uses high intensity laser irradiation and low light absorption.
Study NCT06113146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultra-processed slow eating rate diet
Description: Consuming ultra-processed slow eating rate meals (served ad libitum) and snacks. Eating rate is manipulated through food texture, for example foods with a hard texture that require a long chewing duration before a bite of food can be swallowed.
Study NCT04711720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VTS surgical navigation system
Description: TheVTS surgical navigation system can accurately match the preoperative and intraoperative image data with the patient's anatomical structure on the operating table, track the surgical instruments during the operation, and update the position of the surgical instruments on the patient's image in real time, so that the doctor can clearly understand the position of the surgical instruments relative to the patient's anatomical structure, and make the operation procedure more accurate and safer.
Study NCT04920526 — intervention group
Intervention type: DRUG
Intervention: Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine
Description: No intervention will be administered
Study NCT04277247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: A standardized dose will be injected in each muscle: 25 Units of BTXA in the extensor hallucis longus in 1 site, 50 Units of BTXA in the flexor digitorum brevis in 2 sites and 25 Units of BTXA in the tibialis posterior in 1 site.
Study NCT04277247 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline placebo injection
Study NCT05640089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI-based neurofeedback
Description: Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to positive affective pictures (as identified during a functional localiser scan).
Study NCT05370092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percutaneous needle electrolysis
Description: Electrolysis is the process by which water (H2O) and sodium chloride (NaCl) molecules, which are present in the biological tissues and body compartments of our organism, are organically broken down into their constituent chemical elements, regrouping to create entirely new substances such as sodium hydroxide (NaOH), hydrogen gas (H2) and chlorine gas (Cl2). This process occurs thanks to the passage of a flow of direct electric current, also known as galvanic current, which is a totally athermal process. The passage of this current allows a local inflammatory response to occur (increase in lymphocytes and macrophages) as well as an increase in vasodilatation, inducing phagocytosis and biological stimulation of tendon repair.
Study NCT05370092 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercise
Description: The first exercise they will perform will be the Short-Foot Exercise holding the position 5 seconds isometrically. The second exercise will be plantar flexion of the ankle with adduction of the foot and inversion with elastic band in its concentric and eccentric phase
Study NCT05370092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: The first exercise they will perform will be the Short-Foot Exercise holding the position 5 seconds isometrically. The second exercise will be plantar flexion of the ankle with adduction of the foot and inversion with elastic band in its concentric and eccentric phase
Study NCT05370092 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: The manual therapy (TM) treatment for tendinopathies is mainly focused on soft tissue mobilization and deep transverse friction massage (Cyriax).
Study NCT05370092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: The manual therapy (TM) treatment for tendinopathies is mainly focused on soft tissue mobilization and deep transverse friction massage (Cyriax).
Study NCT06113146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultra-processed fast eating rate diet
Description: Consuming ultra-processed fast eating rate meals (served ad libitum) and snacks. Eating rate is manipulated through food texture, for example foods with a soft texture that require little chewing before a bite of food can be swallowed.
Study NCT05857267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzolamide / Timolol Ophthalmic Solution
Description: Dorzolamide-timolol fixed combination in a preservative-free multidose device
Study NCT05857267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dorzolamide/timolol
Description: Dorzolamide-timolol BAK-preserved fixed combination
Study NCT06186245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early feeding with an oral diet
Description: Participants in the treatment arm will be initiated on a clear liquid diet on day 1 of medical ICU admission. Diet will be progressed on day 2 to full liquid diet or diabetic diet as patient tolerates based on which diet the patient would prefer.
Study NCT04795128 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IBI322
Description: Recombinant anti-human CD47/PD-L1 bispecific antibody injection
Study NCT06488625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-Dose CICR-NAM
Description: 2 g/d CICR-NAM (blinded)
Study NCT06488625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-Dose CICR-NAM
Description: 3 g/d CICR-NAM (blinded)
Study NCT06488625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0 g/d CICR-NAM (blinded)
Description: Placebo (blinded)
Study NCT06488625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-Label
Description: 3 g/d CICR-NAM (open label)
Study NCT05232669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa extract
Description: 2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
Study NCT05232669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa extract placebo
Description: Cocoa extract placebo
Study NCT05232669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa extract placebo
Description: Cocoa extract placebo
Study NCT05232669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: Multivitamin
Study NCT05232669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin placebo
Description: Multivitamin placebo
Study NCT05232669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Multivitamin placebo
Description: Multivitamin placebo
Study NCT06510348 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplemental Parenteral Nutrition (SPN)
Description: Nutritional targets are based on ESPEN guidelines recommendation (calories administration based on indirect calorimetry study, proteins 1.3 g/kg/day). From the first day of ICU admission indirect calorimetry will be performed daily in order to evaluate energy requirements. On the fourth day, the patient will undergo a gastric residual volume measurement and a paracetamol absorption test. If gastrointestinal dysfunction is detected, the patient will be assigned to a study group based on the randomization protocol. The SPN group will gradually initiate supplemental parenteral nutrition in order to achieve the target of 80% by the fifth day. Trophic feed will be administered to cover the remaining 20% of the targeted nutrition intake.
Study NCT05139277 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CONVIVO system
Description: Approximately 2-5 minutes following administration of FNa in situ imaging will be performed by the participating surgeon ensuring proper technique. Prior to entering the surgical field, the probe will be covered in a disposable sterile sheath that is manufactured with quality assurance for this purpose. The probe will gently be held against the tissue interface while imaging occurs. Again this will only be in regions that would normally be resected or sampled in routine clinical care. Following image acquisition, a neuropathologist present in the operating room, will review and capture each image.
Study NCT05139277 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional histologic evaluation
Description: Following image acquisition, the tissue region imaged with the CONVIVO system will then be biopsied using biopsy forceps. This will be passed immediately off the surgical field as a research specimen and provided to a member of the research team to be prepared for conventional histologic evaluation. The specimen will be labeled with the deidentified subject and sample number. This sequence will then be repeated for each successive sample.
Study NCT06445218 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Collection of various data from patients' medical file, such as demographic data, diagnostic results, discharge, treatment....
Study NCT04897113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: plasma exchange with albumin
Description: plasma exchange with albumin, two per week, 110% of the circulating plasma volume
Study NCT04897113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: plasma exchange without albumin
Description: plasma exchange without albumin, two per week, 110% of the circulating plasma volume
Study NCT05742919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194-0499
Description: Participants will receive a single s.c. dose of 12 mg NNC0194-0499 on Day 1.
Study NCT05742919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194-0499
Description: Participants will receive a single s.c. dose of 30 mg NNC0194-0499 on Day 1.
Study NCT05742919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC0194-0499
Description: Participants will receive a single s.c. dose of 96 mg NNC0194-0499 on Day 1.
Study NCT05077956 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebrospinal and Blood Serum Semaphorin 4A Levels
Description: Cerebrospinal fluid and serum will be collected at baseline to measure the level of semaphorin 4A.
Study NCT04694612 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Favipiravir
Description: Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19
Study NCT04694612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Favipiravir
Description: Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19
Study NCT04694612 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19
Study NCT04694612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to Remdesivir Injection in the patients with moderate COVID-19
Study NCT05440331 — intervention group
Intervention type: OTHER
Intervention: Training with AnesList©
Description: Training with AnesList© as tool
Study NCT06382311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Pandemic mRNA_Dose level 1
Description: 2 doses of study intervention are administered to participants intramuscularly. If selected as dose level 1 or dose level 2 in Phase 2 Part B, 1 dose is administered to participants.
Study NCT06382311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Pandemic mRNA_Dose level 2
Description: 2 doses of study intervention are administered to participants intramuscularly. If selected as dose level 1 or dose level 2 in Phase 2 Part B, 1 dose is administered to participants.
Study NCT05766189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wastewater vaccine prompts
Description: Social media communications showing levels of SARS-CoV-2 in wastewater
Study NCT03833804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Processing of clinical notes in the EHR data collected during routine care
Description: Clinical notes collected in the first day of hospital admission during usual care as input to natural language processing and machine learning algorithm.
Study NCT06647017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Volta tAN System
Description: Transcutaneous auricular neurostimulation (tAN)
Study NCT06647017 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM Volta tAN System
Description: Participants randomized to the sham group will have an earpiece applied, but stimulation will not be turned on.
Study NCT04191434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flamboyant 125/12
Description: Flamboyant 125/12 capsule
Study NCT04191434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide/formoterol 200/6
Description: Budesonid/formoterol 200/6 capsule
Study NCT04191434 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flamboyant 125/12 Placebo
Description: Flamboyant 125/12 Placebo capsule
Study NCT04191434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 200/6 placebo
Description: Budesonid/formoterol 200/6 Placebo capsule
Study NCT06068244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printed crowns
Description: 3D printed crowns
Study NCT06068244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zirconia crowns
Description: Nu smile zirconia crowns
Study NCT05863195 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV
Study NCT05863195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study NCT05863195 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Given IV
Study NCT05863195 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo SPECT/CT and/or CT
Study NCT05863195 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo SPECT/CT and/or CT
Study NCT05863195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine
Description: Given via HAI pump
Study NCT05863195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV